Evidence map›Paper›PMID 42010254›Full record

Trial reportNature communications2026

Efficacy and safety of albumin combined with endovascular therapy in the treatment of patients with acute ischemic stroke: a randomized clinical trial.

Yuanyuan Liu, Xiao Dong, Wanwan Zhang, Chengbei Hou, Chuanhui Li, Xuehong Chu, Zhengfei Ma, Tingyu Yi, Changming Wen, Yifeng Liu and 13 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06538844 (Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Reperfusion Therapy), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06538844 phase2completednot on this map

Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Reperfusion Therapy

TypeinterventionalSponsorCapital Medical UniversityRan2024 to 2025Enrolled134ConditionsAcute Ischemic StrokeArmsIntravenous infusion of human albumin, Saline
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Yuanyuan Liu *Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
Xiao Dong *Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
Wanwan Zhang *Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
Chengbei HouCenter for Evidence Based Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China.
Chuanhui LiDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
Xuehong ChuDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
Zhengfei MaDepartment of Neurology, Suzhou Municipal Hospital, Anhui Province, China.
Tingyu YiDapartment of Neuro-intervention, Zhangzhou Municipal Hospital; Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian, China.
Changming WenDepartment of Neurology, Nanyang Central Hospital, Henan Province, China.
Yifeng LiuDepartment of Neurology, Nanyang Central Hospital, Henan Province, China.
Jun SunDepartment of Neurology, Nanyang Central Hospital, Henan Province, China.
Jing XuDepartment of Neurology, Maanshan People's Hospital, Maanshan, Anhui Province, China.
Wenbo LiDepartment of Neurology, Luoyang Central Hospital Affiliated To Zhengzhou University, Henan Province, China.
Lei YangDepartment of Neurology, Liaocheng third people's hospital, Shandong Province, China.
Xiaoman ZhangDepartment of Neurology, The First People's Hospital of Zhengzhou, Henan Province, China.
Chaoqun LiDepartment of Neurology, Xihua County People's Hospital, Henan Province, China.
Wenhuo ChenDepartment of Cerebrovascular Disease, Fujian Medical University Union Hospital, Fujian, China.
Ming LiChina-America Institute of Neuroscience and Beijing Institute of Geriatrics, Xuanwu Hospital, Capital Medical University, Beijing, China.ORCID http://orcid.org/0000-0001-5823-8108
Chen ZhouBeijing Institute for Brain Disorders, Capital Medical University, Beijing, China.ORCID http://orcid.org/0000-0002-9705-4237
Yi XuDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.ORCID http://orcid.org/0009-0005-5037-7724
Di WuChina-America Institute of Neuroscience and Beijing Institute of Geriatrics, Xuanwu Hospital, Capital Medical University, Beijing, China. seadi-wu@163.com.ORCID http://orcid.org/0000-0002-2717-7362
Xunming JiDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China. jixm@ccmu.edu.cn.ORCID http://orcid.org/0000-0003-0293-2744
Chuanjie WuDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China. wuchuanjie@ccmu.edu.cn.ORCID http://orcid.org/0000-0002-0494-416X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82271507
6 · The paper itself

Abstract

The safety and efficacy of albumin combined with endovascular therapy for participants with acute ischemic stroke is unknown. This randomized, double blinded, multicenter study was conducted in China and completed in 2025. Eligible participants were randomly assigned in a 1:1 ratio to albumin group (0.5 g/kg; maximum dose 150 mL; intravenously infusion once daily for 4 days) or placebo group (equivalent volume of placebo). The primary endpoint was the change in infarct volume from baseline to day 5. A total of 134 patients were randomized (66 in albumin group and 68 in placebo group) and 134 patients were included in the final analysis. Albumin reduced infarct volume growth from baseline to day 5 compared with placebo (median growth 7.5 mL vs 16.5 mL, adjusted median difference -8.63, 95%CI (-13.85 to -5.07); P = 0.003). The safety outcomes did not differ between the two groups. This work suggests that albumin plus endovascular therapy could significantly reduce infarct volume growth compared with the placebo group, without raising safety concerns. (Funded by the National Natural Science Foundation of China and others; ClinicalTrials.gov registration: NCT06538844.).

Indexed as

AlbuminsBrain IschemiaEndovascular ProceduresIschemic StrokeStrokeAgedChinaCombined Modality TherapyDouble-Blind MethodFemaleHumansMaleMiddle AgedTreatment OutcomeAlbumins

Identifiers

PMID42010254
PMCPMC13279982

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.